As I mentioned in an earlier post on this thread, the only abstract I could find for the April 2018 AACR meeting that had a "Zenith" hit in the search was: 

1394 / 18 - Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer, in which Irfan A. Asangani of University of Pennsylvania listed Zenith in his disclosures. 

The abstract is embargoed until March 14th, at which time we will not only be able to see the abstract for the above title but also the Late Breaking/Clinical Trial abstract titles will be posted. I'm still holding out hope for Zenith having a presentation at AACR for one or both ZEN-3694 mCRPC trials.

In the meantime, I just noticed yesterday that a manuscript by Irfan Asangani's group was published in Cell Reports and has a very similar title as the AACR abstract: "Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer." I glanced at the manuscript abstract and paper but didn't see any mention of Zenith or ZEN-3694. Perhaps the AACR version of this study will have updated data that working in something to do with ZEN-3694 or another Zenith compound. This is completely possible since the original manuscript was first submitted in August 2017 and then re-submitted in revised form in December 2017. Or it could be than Irfan is just a consultant to Zenith.

We'll have to check back next week when the AACR abstracts are posted.

BDAZ